Currently out of the existing stock ratings of Dae Gon Ha, 87 are a BUY (78.38%), 24 are a HOLD (21.62%).

Dae Gon Ha

Work Performance Price Targets & Ratings Chart

Analyst Dae Gon Ha, carries an average stock price target met ratio of 35.21% that have a potential upside of 26.66% achieved within 106 days. Previously, Dae Gon Ha worked at STIFEL.

Dae Gon Ha’s has documented 230 price targets and ratings displayed on 30 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on MIRM, Mirum Pharmaceuticals at 26-Feb-2026.

Wall Street Analyst Dae Gon Ha

Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for EDIT (EDITAS MEDICINE) at 5/4/2022. The price target of $15 was fulfilled within 1 day with a profit of $0.81 (5.12%) receiving and performance score of 51.23.

Average potential price target upside

of $26.53 (69.71%) on MIRM (MIRUM PHARMACEUTICALS).
of $23.46 (100.28%) on RYTM (RHYTHM PHARMACEUTICALS).
of $21.6 (13.58%) on KRYS (KRYSTAL BIOTECH).

AVRO AVROBIO CCXI ChemoCentryx EDIT Editas Medicine FOLD Amicus Therapeutics FRLN Freeline Therapeutics Holdings Plc FULC Fulcrum Therapeutics AGTC Applied Genetic FIXX Homology Medicines ORTX Orchard Therapeutics PLC EQ Equillium PRQR ProQR Therapeutics BV RARE Ultragenyx RCKT Rocket Pharmaceuticals VERV Verve Therapeutics NTLA Intellia Therapeutics RYTM Rhythm Pharmaceuticals APLS Apellis Pharmaceuticals CRBP Corbus Pharmaceuticals KALV Kalvista Pharmaceuticals RETA Reata Pharmaceuticals SRZN Surrozen KRYS Krystal Biotech SLNO Soleno Therapeutics PRME Prime Medicine, Common Stock ABEO Abeona Therapeutics MIRM Mirum Pharmaceuticals AG First Majestic Silver Corp BEAM Beam Therapeutics DBVT DBV Technologies OR Osisko Gold Ro

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Uy Ear (MIZUHO)